SCHEMBL1928026

SCHEMBL1928026

CCC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
L3MBTL1 Q9Y468 2/20 1.00
HPGD P15428 2/20 0.71
ALDH1A1 P00352 5/20 0.65
KDM4E B2RXH2 4/20 0.65
AGTR1 P30556 1/20 0.65
PTPN1 P18031 1/20 0.64
GSK3B P49841 1/20 0.64
USP2 O75604 1/20 0.63
LMNA P02545 3/20 0.62
RAB9A P51151 2/20 0.62
FFAR1 O14842 1/20 0.62
CYP1A2 P05177 1/20 0.62
HIF1A Q16665 1/20 0.62
ERCC5 P28715 1/20 0.60
FEN1 P39748 1/20 0.60
HAO1 Q9UJM8 1/20 0.60
NPC1 O15118 1/20 0.54
GAA P10253 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13267783 1.00 MAPT (1.00) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1
Biphenyl SCHEMBL11880009 0.93 MAPT (0.88) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1
SCHEMBL10389933 0.91 SMN1; SMN2 (0.83) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1
SCHEMBL13410769 0.90 MAPT (0.81) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1
SCHEMBL16178565 0.89 SMN1; SMN2 (0.79) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1
SCHEMBL7860509 0.89 SMN1; SMN2 (0.79) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1
SCHEMBL15085369 0.87 SMN1; SMN2 (0.77) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1
Propiophenone SCHEMBL76464 0.86 SMN1; SMN2 (0.75) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1
Propiophenone SCHEMBL14244535 0.86 SMN1; SMN2 (0.75) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1
Propiophenone SCHEMBL318818 0.86 SMN1; SMN2 (0.75) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120149327-A Solid composite alkali metal negative electrode, preparation method thereof and secondary battery 中国科学院苏州纳米技术与纳米仿生研究所 2025-06-13 CN claimed
US-9884936-B2 Photoactive resins, radiation curable compositions and radiation curable inks SUN CHEMICAL CORPORATION (US) 2018-02-06 US claimed
CN-104066758-B Photoreactive resin, radiation curable composition and radiation-curable ink 太阳化学公司 2016-08-31 CN claimed
EP-2785754-B1 PHOTOACTIVE RESINS, RADIATION CURABLE COMPOSITIONS AND RADIATION CURABLE INKS SUN CHEMICAL CORP (US) 2016-07-06 EP claimed
US-20140315002-A1 PHOTOACTIVE RESINS, RADIATION CURABLE COMPOSITIONS AND RADIATION CURABLE INKS SUN CHEMICAL CORPORATION (US) 2014-10-23 US claimed
EP-2785754-A1 PHOTOACTIVE RESINS, RADIATION CURABLE COMPOSITIONS AND RADIATION CURABLE INKS Sun Chemical Corporation (US) 2014-10-08 EP claimed
CN-104066758-A Photoactive resins, radiation curable compositions and radiation curable inks SUN CHEMICAL CORP 2014-09-24 CN claimed
WO-2013082262-A1 PHOTOACTIVE RESINS, RADIATION CURABLE COMPOSITIONS AND RADIATION CURABLE INKS SUN CHEMICAL CORPORATION (US) 2013-06-06 WO claimed
EP-0015221-B1 PROCESS FOR THE PREPARATION OF PARA-BENZOQUINONES RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1981-12-02 EP claimed
JP-61246088-A None JP disclosed
CN-120149327-A Solid composite alkali metal negative electrode, preparation method thereof and secondary battery 中国科学院苏州纳米技术与纳米仿生研究所 2025-06-13 CN disclosed
WO-2023142996-A1 METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT 上海岸阔医药科技有限公司 2023-08-03 WO disclosed
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L-Base Co., Ltd. (KR) 2023-05-25 US disclosed
CN-112358380-B Synthesis method of 4- (4' -alkylcyclohexyl) cyclohexanol 惠泽化学科技(濮阳)有限公司 2023-03-31 CN disclosed
US-4680299-A ANTITUMOR AGENTS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-07-14 US disclosed
JP-S61246088-A THERMAL RECORDING MATERIAL NIPPON KAYAKU CO LTD 1986-11-01 JP disclosed
EP-0133244-A2 Phenylquinolinecarboxylic acids and derivatives as antitumor agents E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-02-20 EP disclosed
EP-0015221-B1 PROCESS FOR THE PREPARATION OF PARA-BENZOQUINONES RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1981-12-02 EP disclosed
US-4275071-A Imidazole derivatives RECORDATI S.A. (CH) 1981-06-23 US disclosed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER VIP, QPCT, TPT1 MAPT 633/4885SMN1; SMN2 3079/4885L3MBTL1 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.